<DOC>
	<DOCNO>NCT00451997</DOCNO>
	<brief_summary>The goal clinical research study learn combination Gleevec ( imatinib mesylate ) low dos Cytarabine ( ara-C ) may help control leukemia cause few side effect standard high dose chemotherapy .</brief_summary>
	<brief_title>Gleevec/Low-Dose Ara-C Study Elderly Patients With AML Myelodysplastic Syndromes</brief_title>
	<detailed_description>Imatinib mesylate drug block certain protein . This protein think important growth leukemia cell . Ara-C chemotherapy drug use many year treat AML MDS . Imatinib mesylate ( Gleevec ) protein-tyrosine kinase inhibitor inhibit Bcr-Abl tyrosine kinase , well receptor tyrosine kinases platelet- derived growth factor ( PDGF ) stem cell factor ( SCF ) , c-Kit , inhibits PDGF- SCF-mediated cellular event . c-Kit express 90 % patient AML . The treatment AML patient age 65 old AML high-risk MDS ( age Â³ 60 high-risk cytogenetics ) poor prognosis induction chemotherapy . Response rate 45 % induction mortality least 25 % , 1-year survival well 20 % . Indeed , patient age group even offer therapy manage supportive care . Thus , new therapy well tolerate need . Imatinib alone induce response nearly 20 % patient , synergy low concentration ara-C . In study plan investigate combination imatinib low-dose ara-C .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients candidate intensive chemotherapy follow diagnosis : 1 . AML MDS ( &gt; /=5 % blast ) age &gt; /= 65 year old ( age &gt; /= 60 highrisk cytogenetics ) , 2 . AML MDS ( RAEB RAEBT ) cytogenetic group age 60 old minimally treat disease relapse disease refractory therapy likely require cytoreductive therapy within one month , , 3 . CMML . Patients WHO performance status 0 2 Patients must recover prior cytotoxic chemotherapy ; treatment hydrea allow 24 hour prior day 1 study drug administration Written inform consent obtain accord local guideline Patients must serum creatinine &lt; /= 1.5 x ULN , SGPT &lt; /= 3 x ULN total bilirubin &lt; /= 2.0 x ULN . Patients &gt; /= 20 % blast positive ckit ( CD117 ) ( except CMML ) Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient childbearing potential must agree employ effective method birth control throughout study 3 month follow discontinuation study drug . Patients uncontrolled active infection Patients NYHA class III IV Women pregnant Women breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Ara-C</keyword>
	<keyword>C-Kit Positive Acute Myeloid Leukemia</keyword>
	<keyword>High-Risk Myelodysplastic Syndromes</keyword>
</DOC>